Delivery of Adriamycin Loaded Niosomes for Liver Cancer Treatment

The delivery efficiency of Adriamycin is crucial for the therapy of hepatocellular carcinoma. Niosome is a promising carrier that can be used for targeted drug delivery. However, the therapeutic effect of Adriamycin loaded niosome is still unclear. In this study, Adriamycin loaded niosomes were constructed as a promising drug carrier system. The morphological determination of niosomes was conducted by transmission electron microscopy. Cell fluorescence was used for cellular uptake analysis. Western blotting was used to estimate the apoptosis-related protein expression in HepG2 cells. 3-(4,5)-di-methylthiahiazo(-z-y1)-3,5-di-phenytetrazolium bromide assay was used for estimating the apoptosis of cancer cells. The in vivo anti-cancer effect and safety of Adriamycin loaded niosomes were analyzed in tumor-bearing mice. Adriamycin loaded niosomes improved the cellular uptake of Adriamycin. The anti-cancer effect of Adriamycin in vivo was enhanced. The responsive release of Adriamycin loaded niosomes under acidic conditions reduced the toxicity of Adriamycin to IP 846247 10 On: Mon, 2 De 2022 06:1449 normal cells and the mortality of tumor-bearing mice. Together, Adriamycin loaded niosomes improved its anti-cancer Copyright Am rican Sc entific Pubishers effect and safety for liver cancer treatment.

Automated summary

This study investigated the application of Adriamycin-loaded niosomes in the treatment of liver cancer. The results demonstrated that Adriamycin-loaded niosomes improved cellular uptake of Adriamycin, enhanced its anti-cancer effect in vivo, and reduced the toxicity to normal cells and mortality in tumor-bearing mice through responsive release under acidic conditions.